Breaking News

Cytovance to Expand Bio-Manufacturing Capabilities

Cytovance Biologics has secured financing of $22.5 million from Great Point Partners, LLC to invest in the expansion its biologic manufacturing capabilities in Oklahoma City.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cytovance Biologics has secured financing of $22.5 million from Great Point Partners, LLC to invest in the expansion its biologic manufacturing capabilities in Oklahoma City. The investment will enable Cytovance to expand its clinical trial and commercial scale cGMP manufacturing by funding facility, service and personnel expansion at its research and manufacturing operation in Oklahoma City. Cytovance will move to a nearby facility with laboratories recently vacated by Genzyme. Cytovance al...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters